X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Lenalidomide, a therapeutic equivalent generic version of REVLIMID, and a thalidomide analogue, caused limb abnormalities in developmental monkey study similar to birth defects caused by thalidomide in humans.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Lenalidomide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Dr. Reddy received ANDA approval for lenalidomide capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of Revlimid.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Revlimid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.
Lead Product(s): Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Revlimid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
Sarclisa (isatuximab) is a CD38 monoclonal antibody in combination with standard-of-care bortezomib, lenalidomide and dexamethasone is being evaluated in newly diagnosed multiple myeloma not eligible for transplant.
Lead Product(s): Isatuximab,Lenalidomide,Bortezomib
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
ALX Oncology lead product candidate ALX148 (evorpacept) in combination with Rituximab and Lenalidomide is being evaluated with patients for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Lead Product(s): Evorpacept,Rituximab,Lenalidomide
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
Pfizer's Adcetris (brentuximab vedotin), CD30 inhibitor, which is being evaluated in Phase III clinical trial studies in combination with Lenalidomide and Rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Lead Product(s): Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
Johnson-approved product Darzalex (daratumumab), which is a CD38 inhibitor, currently it is being evaluated in Phase III clinical trials in combination with bortezomib, lenalidomide, dexamethasone for the treatment of multiple myeloma.
Lead Product(s): Daratumumab,Bortezomib,Lenalidomide
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone is being evaluated in phase 3 clinical trials for the maintenance treatment of adult patients who are newly diagnosed with multiple myeloma.
Lead Product(s): Daratumumab,Hyaluronidase,Lenalidomide
Therapeutic Area: Oncology Product Name: Darzalex Faspro
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
Minjuvi (tafasitamab) is a humanized Fc-modified cytolytic CD19-targeting immunotherapy, which is approved in combination with lenalidomide has been approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Minjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2024
Details:
STAR-LLD is a continuous delivery lenalidomide (LLD), which is under phase 1 clinical development to expand and replace the standard of care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL).
Lead Product(s): Lenalidomide,Dexamethasone,Bortezomib
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
STAR-LLD is a continuous delivery lenalidomide in development to expand and replace the standard of care for the most common blood cancers, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
Lead Product(s): Lenalidomide,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: STAR-LDD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
The Company remains focused and committed to the completion of its Phase 1b STAR-LLD clinical trial in multiple myeloma study in order to bring patients a potentially superior delivery of continuous subcutaneous administration of lenalidomide.
Lead Product(s): Lenalidomide,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: STAR-LDD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Healthwell Acquisition Corp. I
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination November 03, 2023
Details:
STAR-LLD uses novel treatment modalities of continuous delivery of low-dose lenalidomide. Immunomodulatory drugs (IMiDs) are the mainstay of early treatment in a number of hematologic malignancies – such as multiple myeloma and lymphomas.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
STAR-LLD uses novel treatment modalities of continuous delivery of low-dose lenalidomide, which is investigated for the treatment of multiple myeloma and lymphomas.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
Under the agreement, Starton will conduct its Phase 1b trial of STAR-LLD, a continuous delivery lenalidomide in development to replace the standard of care for multiple myeloma and chronic lymphocytic leukemia in multiple myeloma, with a global CRO.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 10, 2023
Details:
MDX-1097 (kappamab) targets a receptor called Kappa Myeloma Antigen (KMA) found only on the surface of myeloma cells in in combination with lenalidomide and dexamethasone in kappa-type multiple myeloma patients who had relapsed or become refractory to other treatment options.
Lead Product(s): KappaMab,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: MDX-1097
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Monjuvi® and Minjuvi® (tafasitamab) is a humanized Fc-modified CD19 targeting immunotherapy used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Minjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
GEN3013 (epcoritamab-bysp) is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody® technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells, which is used for Diffuse Large B-cell Lymphoma.
Lead Product(s): Epcoritamab-bysp,Rituximab,Lenalidomide
Therapeutic Area: Oncology Product Name: GEN3013
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
STAR-LLD uses novel treatment modalities of continuous delivery of low-dose lenalidomide. Immunomodulatory drugs (IMiDs) are the mainstay of early treatment in a number of hematologic malignancies – such as multiple myeloma and lymphomas.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
ANV419 is a powerful, IL-2Rβ selective IL-2 agonist, which has been specifically designed to enable the delivery of high dose IL-2. It stimulates the expansion of natural killer (NK) and cytotoxic CD8+ T cells in patients with multiple myeloma.
Lead Product(s): ANV419,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: ANV419
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
Lenalidomide modulates the substrate specificity of CRL4CRBN E3 ubiquitin ligase. Subsequent proteasomal degradation of these transcription factors kills multiple myeloma cells.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Revlimid-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2023
Details:
Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and del (5q) myelodysplastic syndromes, follicular lymphoma and marginal zone lymphoma.
Lead Product(s): Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Lenalidomide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
Lenalidomide (revlimid's-generic) activates NK cells, which leads to heightened immune surveillance the ability of the immune system to both identify and eliminate tumor cells. Lenalidomide has tumoricidal effects on multiple myeloma.
Lead Product(s): Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Revlimid-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and del (5q) myelodysplastic syndromes, follicular lymphoma and marginal zone lymphoma.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Revlimid-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
Ninlaro® (ixazomib) is the first and only oral proteasome inhibitor licensed in combination with lenalidomide and dexamethasone for adults with multiple myeloma (MM).
Lead Product(s): Ixazomib,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Ninlaro
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Monjuvi® and Minjuvi® (tafasitamab) is a humanized Fc-modified CD19 targeting immunotherapy used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Monjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. Tafasitamab is a humanized Fc-modified CD19 targeting immunotherapy.
Lead Product(s): Orelabrutinib,Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Hibruka
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
Recently published results from a Phase 1 trial conducted by ONCOtherapeutics among 28 heavily previously treated MM patients administered RUX, lenalidomide (LEN) and MP demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroids.
Lead Product(s): Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area: Oncology Product Name: Jakafi
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
DARZALEX® (daratumumab) received U.S. FDA approval in November 2015 and is approved in eight indications in multiple myeloma, three of which are in the frontline setting, including newly diagnosed patients who are transplant eligible and ineligible.
Lead Product(s): Daratumumab,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
The data suggest that changing the delivery of lenalidomide to a continuous subcutaneous infusion improves tumor control and tumor volume in lenalidomide resistant tumors.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
Plamotamab (XmAb13676), is generally well tolerated and demonstrates encouraging clinical activity at our recommended intravenous Phase 2 dose, 50 mg flat dosing every two weeks after step-up dosing.
Lead Product(s): Plamotamab,Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: XmAb13676
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Updated results from the phase II NP30179 study will show a fixed course of glofitamab monotherapy can deliver durable complete responses in people with heavily pre-treated aggressive lymphomas.
Lead Product(s): Glofitamab,Poseltinib,Lenalidomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
The body of data presented at SOHO shows the long-term duration of response to Monjuvi (tafasitamab) in some patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem-cell transplant.
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Monjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
Monjuvi (tafasitamab) incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity and Antibody-Dependent Cellular Phagocytosis.
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Monjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: MorphoSys
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
Lenalidomide is an immunomodulatory prescription drug which is indicated for several hematological malignancies in adults such as; Multiple Myeloma, Myelodysplastic syndromes, Mantle cell lymphoma, Follicular lymphoma, and Marginal Zone lymphoma.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Lenalidomide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Minjuvi (tafasitamab) incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Minjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
Details:
In primary analysis, GRIFFIN study met primary endpoint, resulting in higher stringent complete response rate for DARZALEX®-RVd (daratumumab) compared with RVd alone by end of post-autologous stem cell transplant consolidation therapy meeting prespecified 1-sided alpha of 0.1.
Lead Product(s): Daratumumab,Lenalidomide,Bortezomib
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2022
Details:
Minjuvi (tafasitamab) incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Minjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
A preclinical proof-of-concept study for STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with pulsatile i.p. lenalidomide administration and shrank by 80% with STAR-LLD over the 29-day dosing interval.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers.
Lead Product(s): EO2463,Rituximab,Lenalidomide
Therapeutic Area: Oncology Product Name: EO2463
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
Under the terms of the new agreements, HIBio will obtain exclusive rights to develop and commercialize MOR202 (felzartamab) and TJ210 across all indications worldwide, excluding Greater China for felzartamab and Greater China and South Korea for TJ210.
Lead Product(s): Felzartamab,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: MOR202
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: I-Mab Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 15, 2022
Details:
Under the terms of the agreement, Pfizer will initiate a multicenter, international Phase 1b/2 study of TTI-622 with Monjuvi and lenalidomide for patients with relapsed or refractory DLBCL who are not eligible for ASCT.
Lead Product(s): TTI-622,Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: TTI-622
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 13, 2022
Details:
JNJ-64007957 (teclistamab) is an investigational, fully humanized IgG4, T-cell redirecting, bispecific antibody targeting both BCMA (B-cell maturation antigen) and CD3, the T-cell receptor. BCMA is expressed at high levels on multiple myeloma cells.
Lead Product(s): Teclistamab,Lenalidomide
Therapeutic Area: Oncology Product Name: JNJ-64007957
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
Treatment with Tazverik (tazemetostat) and R2 was generally well tolerated and the adverse events were consistent with those contained in the prescribing information for both tazemetostat and R2, respectively.
Lead Product(s): Tazemetostat,Rituximab,Lenalidomide
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
Updated results from the TRIMM-2 study of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma will be presented in an oral session.
Lead Product(s): Teclistamab,Lenalidomide
Therapeutic Area: Oncology Product Name: JNJ-64007957
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
XPOVIO® (selinexor) is the first and only oral XPO1 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Lead Product(s): Selinexor,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
A preclinical proof-of-concept study for STAR-LLD (lenalidomide) demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with oral lenalidomide and shrank by 80% with STAR-LLD.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Monjuvi (tafasitamab-cxix), is a humanized Fc-modified CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab.
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Monjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
STAR-LLD is a continuous delivery lenalidomide in development to expand the standard of care for the most common blood cancers, multiple myeloma and chronic lymphocytic leukemia.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
STAR-LLD, a continuous delivery lenalidomide in preclinical study it demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with oral lenalidomide and shrank by 80% with STAR-LLD.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
